GATT Technologies' hemostatic sealant patch undergoes successful FIH

Hemostatic sealant solutions innovator GATT Technologies has announced the successful first-in-human (FIH) of its lead product GATT-Patch — a sponge coated with a special polymer — used to resolve bleeding in a patient undergoing liver resection surgery by Radboud university medical center Nijmegen (Radboudumc). 

This first patient marks the start of a multicenter clinical trial that will be conducted by three leading academic medical centers in the Netherlands: Radboudumc, The University Medical Center Groningen, who have both already treated patients in the trial, and Erasmus Medical Centrum Rotterdam Mis intending to join shortly.

"This product fills an important clinical need. Having fast and effective solutions to manage complex bleeding is crucial to prevent complications for patients during or after surgery. Hemostats and sealants are used when other methods to contain the bleeding are ineffective or insufficient. Current products on the market have limitations in their ease of use, may not always be able to stop the bleeding, and are also costly. This product aims to address all these limitations," said Professor dr. Hans de Wilt, surgeon at Radboudumc and principal investigator of the GATT-Patch clinical trial. 

The start of its first clinical trial marks an important milestone for the company: "Based on our patented synthetic polymer technology, we are convinced of the opportunities of our platform. All pre-clinical work performed in the past years has confirmed safety and superior performance of GATT-Patch. It is very exciting to now see our lead product used on patients, which will give us vital data regarding the safety and performance of GATT-Patch in a clinical setting," said Johan Bender, founder and CTO of GATT.